Avalyn Pharma publishes Phase 1 AP02 data; Phase 2 topline late 2027
Avalyn Pharma said Phase 1 AP02 data showed higher predicted lung exposure with lower systemic exposure versus oral nintedanib, and that Phase 2 AURA enrollment is on track for topline data expected late 2027.
Avalyn Pharma Inc. said Phase 1 data for lung-targeted AP02 showed higher predicted lung exposure and lower systemic exposure versus oral nintedanib. The company said enrollment in Phase 2 AURA is on track, with topline data expected late 2027.